Patient-derived NRAS mutated (BAK and BUL) and BRAF mutated (STU) melanoma cell lines were exposed to increasing concentrations of the MEK1/2 inhibitor trametinib (T), MBZ or a combination of T + MBZ. Here, BRAF is linked to melanoma.